Immune Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 5 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
About Immune Biotech
Immune Biotech Private Limited (IBPL) is a Private Limited Indian Non-Government Company incorporated in India on 21 November 2019 (Five years and three months 4 days old ). Its registered office is in Nagpur, Maharashtra, India.
The Company is engaged in the Manufacturing Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Kareem Kureshi and Shaba Kureshi serve as directors at the Company.
Company Details
- Location
Nagpur, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U36999MH2019PTC333404
- Company No.
333404
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
21 Nov 2019
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
What products or services does Immune Biotech Private Limited offer?
Immune Biotech Private Limited offers a wide range of products and services, including Anti Infective Drugs & Medicines, Antiviral Drugs, Cardiovascular Drugs & Medication, Kidney Drugs, Immunosuppressive Drugs, Pain Relief Drugs & Pharmaceuticals, Anti Inflammatory Drugs.
Who are the key members and board of directors at Immune Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Kareem Kureshi  | Director | 21-Nov-2019 | Current |
| Shaba Kureshi | Director | 09-Jan-2020 | Current |
Financial Performance of Immune Biotech.
Immune Biotech Private Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets | |||||||
| Profit or Loss | |||||||
| Net Worth | |||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Immune Biotech?
Unlock access to Immune Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Immune Biotech?
Unlock and access historical data on people associated with Immune Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Immune Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Immune Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
